Literature DB >> 34339028

Epithelial Ovarian Cancer and Cancer Stem Cells.

Amr A Soliman1, Alaa A Elzarkaa2, Eduard Malik3.   

Abstract

Epithelial ovarian cancer is a lethal gynecological cancer. It is related to high mortality because the majority of the patients present in advanced stage and because of the high recurrence rates of the disease. Recurrent ovarian cancer is classified according to the time interval between the last platinum-based chemotherapy and the occurrence of recurrence, to platinum-sensitive and platinum-resistant. Many theories tried to explain development of resistance to platinum-based therapy. "Cancer stem cells" is one of these theories and is being currently under investigation by many groups. This chapter will demonstrate the suggested contribution of cancer stem cells to the development of recurrent ovarian cancer.
© 2021. Springer Nature Switzerland AG.

Entities:  

Keywords:  Cancer stem cells; Chemotherapy resistance; Ovarian cancer; Treatment

Year:  2021        PMID： 34339028     DOI： 10.1007/978-3-030-73359-9_2

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN： 0065-2598            Impact factor:   2.622


  74 in total

1.  A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

Authors:  Andreas du Bois; Hans-Joachim Lück; Werner Meier; Hans-Peter Adams; Volker Möbus; Serban Costa; Thomas Bauknecht; Barbara Richter; Matthias Warm; Willibald Schröder; Sigrid Olbricht; Ulrike Nitz; Christian Jackisch; Günther Emons; Uwe Wagner; Walther Kuhn; Jacobus Pfisterer
Journal:  J Natl Cancer Inst       Date:  2003-09-03       Impact factor: 13.506

2.  Intra-abdominal tumor dissemination pattern and surgical outcome in 214 patients with primary ovarian cancer.

Authors:  Jalid Sehouli; Filiz Senyuva; Christina Fotopoulou; Ulf Neumann; Carsten Denkert; Lichtenegger Werner; Oskay-Ozcelik Gülten
Journal:  J Surg Oncol       Date:  2009-06-01       Impact factor: 3.454

3.  Prognostic impact of debulking surgery and residual tumor in patients with epithelial ovarian cancer FIGO stage IV.

Authors:  Beyhan Ataseven; Christoph Grimm; Philipp Harter; Florian Heitz; Alexander Traut; Sonia Prader; Andreas du Bois
Journal:  Gynecol Oncol       Date:  2015-12-12       Impact factor: 5.482

4.  Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.

Authors:  M J Piccart; K Bertelsen; K James; J Cassidy; C Mangioni; E Simonsen; G Stuart; S Kaye; I Vergote; R Blom; R Grimshaw; R J Atkinson; K D Swenerton; C Trope; M Nardi; J Kaern; S Tumolo; P Timmers; J A Roy; F Lhoas; B Lindvall; M Bacon; A Birt; J E Andersen; B Zee; J Paul; B Baron; S Pecorelli
Journal:  J Natl Cancer Inst       Date:  2000-05-03       Impact factor: 13.506

5.  Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO).

Authors:  Andreas du Bois; Alexander Reuss; Eric Pujade-Lauraine; Philipp Harter; Isabelle Ray-Coquard; Jacobus Pfisterer
Journal:  Cancer       Date:  2009-03-15       Impact factor: 6.860

6.  The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma.

Authors:  W J Hoskins; W P McGuire; M F Brady; H D Homesley; W T Creasman; M Berman; H Ball; J S Berek
Journal:  Am J Obstet Gynecol       Date:  1994-04       Impact factor: 8.661

7.  A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study.

Authors:  G Omura; J A Blessing; C E Ehrlich; A Miller; E Yordan; W T Creasman; H D Homesley
Journal:  Cancer       Date:  1986-05-01       Impact factor: 6.860

8.  Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study.

Authors:  William E Winter; G Larry Maxwell; Chunqiao Tian; Jay W Carlson; Robert F Ozols; Peter G Rose; Maurie Markman; Deborah K Armstrong; Franco Muggia; William P McGuire
Journal:  J Clin Oncol       Date:  2007-08-20       Impact factor: 44.544

9.  Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial.

Authors:  J Baptist Trimbos; Ignace Vergote; Giorgio Bolis; Jan B Vermorken; Constantino Mangioni; Caterina Madronal; Massimo Franchi; Saverio Tateo; Gerardo Zanetta; Giovanna Scarfone; Livia Giurgea; Petra Timmers; Corneel Coens; Sergio Pecorelli
Journal:  J Natl Cancer Inst       Date:  2003-01-15       Impact factor: 13.506

10.  Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.

Authors:  W P McGuire; W J Hoskins; M F Brady; P R Kucera; E E Partridge; K Y Look; D L Clarke-Pearson; M Davidson
Journal:  N Engl J Med       Date:  1996-01-04       Impact factor: 91.245
View more
  1 in total

1.  PIK3R3, a regulatory subunit of PI3K, modulates ovarian cancer stem cells and ovarian cancer development and progression by integrative analysis.

Authors:  Eun Jung Sohn
Journal:  BMC Cancer       Date:  2022-06-27       Impact factor: 4.638
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.